Smart Biopsy Devices Market

Global Industry Analysis (2018 - 2021) - Growth Trends and Market Forecast (2022 - 2029)

Published Date: Upcoming | Format:

Industry: Medical Devices


Request TOC Request Customization $4,995.00Prebook

Demand for Minimally Invasive Surgical Procedures due to High Prevalence of Cancer Fuels Growth of Smart Biopsy Devices Market

Cancer is now the second leading cause of death worldwide, trailing only cardiovascular disease. Tobacco smoking, urbanisation and its associated pollution, and changing dietary patterns, along with increased wealth associated with better medical services and a longer post-reproductive life span, have been blamed for this phenomenon. There are over 100 different types of cancer, each classified by organs, such as malignant melanoma of the colon and rectum.

According to the Global Cancer Observatory's Globocan 2020 report, which estimated the incidence and mortality of 36 cancers in 185 countries worldwide, there were an estimated 19,292,789 new cases of cancer diagnosed in 2020 and approximately 9,958,133 people died from cancer worldwide. According to the same source, the number of new cancer cases is expected to reach 24,044,406 by 2030, indicating an increasing prevalence of cancer globally. The high prevalence of cancer will necessitate treatment, driving the market growth. As a result, the anticipated increase in cancer burden is a major factor contributing to the rising demand for biopsy, boosting the market growth.

Patients all over the world are increasingly preferring minimally invasive (MI) biopsy procedures. For instance, the MI breast biopsy technique (MIBT) eliminates the need for surgery to diagnose cancer while protecting healthy tissues from radiation damage. The growing acceptance, adoption, and popularity of minimally invasive surgeries are also expected to aid in the growth of the global smart biopsy devices market in the coming years. Furthermore, governments and private health organisations in various countries around the world are taking serious initiatives to raise cancer awareness, and the availability of various cancer therapeutics and diagnoses will help create new growth opportunities for vendors in the global smart biopsy devices market during the forecast period. In March 2022, the Japanese Ministry of Health, Labour, and Welfare approved Guardant360 CDx, a liquid biopsy test for tumour mutation profiling, also known as comprehensive genomic profiling, in patients with advanced solid tumours (MHLW).

Rising Awareness in Females Regarding Breast Cancer to Make it Ideal for Smart Biopsy Devices

Breast cancer is expected to be the fastest-growing segment of the smart biopsy devices market over the forecast period. This cancer begins in breast cells, which usually form in lobules or ducts. Breast cancer symptoms included breast pain, pitted skin over the entire breast, blood discharge from nipples, inverted nipples, and underarm swelling. Breast cancer is the most common cancer in low- and middle-income countries due to a lack of awareness among women. As a result, rising female awareness, as well as increased availability and affordability of diagnostic procedures, are expected to drive demand for smart biopsy devices in the breast cancer segment. Due to the growing number of patients suffering from malignant skin tumours, the skin cancer segment is expected to grow at the fastest CAGR in the coming years. Skin cancer is caused by two main factors. UV radiation exposure and the use of UV tanning machines can cause multiple mutations in skin cells.

Rising Number of Cancer Patients in Market Players North American to Drive Growth of Smart Biopsy Devices Market

Dominance of North America is likely to continue over the forecast period due to the rising number of cancer cases, the availability of financing for cancer-related research and development, the presence of important market players, and increased initiative by leading market participants, Furthermore, National Breast Cancer Awareness Month (NBCAM), which is organised by major breast cancer charities in the United States, raises awareness about the causes and prevention of breast cancer. All of these elements are expected to drive regional demand for smart biopsy devices.

One of the primary elements driving market expansion is increased funding from governmental and private entities. For instance, according to the National Institutes of Health (NIH) 2020 predictions, total funding for breast cancer research in the United States was USD 709 million in 2019, and USD 768 million in 2020. Similarly, Canada's overall health spending in 2019 was USD 208.2 billion, according to the Organisation for Economic Co-operation and Development (OECD).

Due to increasing government initiatives, healthcare spending, cancer awareness campaigns, and the availability of technologically enhanced smart biopsy devices, Asia Pacific is expected to have the fastest CAGR during the forecast period. Initiatives undertaken by the government and global health organisations contribute to market growth. For instance, the Indian government announced two major healthcare initiatives, Ayushman Bharat and the National Health Protection Scheme. As a result of the aforementioned factors, the smart biopsy devices market is expected to grow in the future.

Global Smart Biopsy Devices Market: Competitive Landscape

Companies in the global smart biopsy devices market are introducing new products alongside initiation collaborations, alliances and partnership agreements. For instance, in April 2022, Guardant Health, Inc. partnered with Epic, the nation's most widely used comprehensive health record, to integrate the company's extensive cancer test portfolio with Epic. On the other hand, in March 2021, Izi Medical Product introduced the Quick-Core-Auto Biopsy System, which is fully automated. This will strengthen the company's product portfolio and market position.

A few of the players in the smart biopsy devices market include Argon Medical, B. Braun Melsungen AG, Canon medical systems corporation, Cook Medical, Danaher, IMS Giotto S.p.A, INRAD, Inc., Becton, Dickinson and Company, Boston Scientific Corporation, C. R. Bard, Intuitive Surgical and PLANMED OY.

Global Smart Biopsy Devices Market is Segmented as Below:

By Application

  • Breast Cancer
  • Liver Cancer
  • Skin Cancer
  • Prostate Cancer
  • Others

By End User

  • Hospitals
  • Academic and Research Institutes
  • Diagnostic and Imaging Centres

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Japan
    • South Korea
    • India
    • China
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa

Key Elements Included In The Study: Global Smart Biopsy Devices Market

  • Smart Biopsy Devices Market by Product/Technology/Grade, Application/End-user, and Region
  • Executive Summary (Opportunity Analysis and Key Trends)
  • Historical Market Size and Estimates, Value, 2018 - 2021
  • Market Value at Regional and Country Level, 2022 - 2029
  • Market Dynamics and Economic Overview
  • Market Size in Value, Growth Rates, and Forecast Figures, 2022 - 2029
  • Competitive Intelligence with Financials, Key Developments, and Portfolio of Leading Companies 
  • Regional and Product/Grade/Application/End-user Price Trends Analysis
  • Value Chain and Five Force’s Analysis
  • Regional/Sub-region/Country Market Size and Trend Analysis
  • Company Market Share Analysis and Key Player Profiles

Post Sale Support, Research Updates & Offerings

We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.

  • The report will be prepared in a PPT format and will be delivered in a PDF format.
  • Additionally, Market Estimation and Forecast numbers will be shared in Excel Workbook.
  • If a report being sold was published over a year ago, we will offer a complimentary copy of the updated research report along with Market Estimation and Forecast numbers within 2-3 weeks’ time of the sale.
  • If we update this research study within the next 2 quarters, post purchase of the report, we will offer a Complimentary copy of the updated Market Estimation and Forecast numbers in Excel Workbook.
  • If there is a geopolitical conflict, pandemic, recession, and the like which can impact global economic scenario and business activity, which might entirely alter the market dynamics or future projections in the industry, we will create a Research Update upon your request at a nominal charge.

Disclaimer:

  • The segmentation/company profiles/countries depicted above may vary in the actual report.

Request Table of Contents

Our Research Methodology

Considering the volatility of business today, traditional approaches to strategizing a game plan can be unfruitful if not detrimental. True ambiguity is no way to determine a forecast. A myriad of predetermined factors must be accounted for such as the degree of risk involved, the magnitude of circumstances, as well as conditions or consequences that are not known or unpredictable. To circumvent binary views that cast uncertainty, the application of market research intelligence to strategically posture, move, and enable actionable outcomes is necessary.

View Methodology
Fairfield Quality assured
Fairfield Confidentiality assured
Fairfield Custom research services